RATIONALE: Scientific and regulatory organizations now emphasize a sex-specific approach to disease research and treatment. Benralizumab Phase III trials provide an opportunity to examine sex-specific disease attributes in a well-defined population with severe asthma. METHODS: This was a post-hoc analysis of pooled data from SIROCCO (48 weeks; NCT01928771) and CALIMA (56 weeks; NCT01914757) (patients: 12-75 years old; > _2 historical exacerbations; high-dosage ICS/ LABA use). Patients received benralizumab 30 mg subcutaneously Q4W or Q8W (first 3 doses Q4W) or placebo. We compared baseline characteristics of female and male patients with baseline blood eosinophil counts > _300 cells/mL. No a priori formal statistical analyses were tested. Unless otherwise stated, continuous data are mean (SD); dichotomous data are percentages. RESULTS: Of 1,537 patients, 969 (63%) were women. Mean ages (years) were: women, 49.4 (13.1); men, 48.1 (14.9). BMIs (kg/m 2 ) were: women, 29.2 (7.4); men, 27.7 (5.0). Median IgE concentrations (kU/L) (25th, 75th percentile) were: women, 186.5 (66.5, 475.4); men, 262.2 (106.7, 635.8). Percentages of patients with 2 and > _3 exacerbations in the year prior to study entry were: women, 58.5% and 41.5%; men, 63.9% and 36.1% respectively. Percentages who were atopic by Phadiatop screen, had comorbid nasal polyps, and had gastroesophageal reflux, respectively, were: women, 57.9%, 19.8%, and 27.9%; men, 66.9%, 25.7%, and 19.4%. Prebronchodilator FEV 1 (% predicted normal) was 57.4 (14.0) for women and 56.5 (14.7) for men. CONCLUSIONS: Baseline characteristics of women and men with baseline blood eosinophil counts > _300 cells/mL were similar. Numerical differences in IgE, atopy, and number of historical exacerbations were observed. Monoclonal therapy would be a promising option for these patients. The objective of the study was to evaluate the possible indications of these licensed biologicals for patients with AERD. METHODS: Retrospective study of adult patients being followed up at an asthma outpatient clinic with a history of AERD. All patients had nasal polyposis, rhinosinusitis, asthma, NSAID hypersensitivity, and sporadic exacerbation of the clinical condition. The clinical characteristics, asthma severity, peripheral eosinophilia, total and specific IgE for aeroallergens were analyzed, classifying them according to the current criteria in the label for monoclonal therapies. RESULTS: A total of 61 patients were included, 75% female, with age of 55.7 years. Twenty-eight patients (45.9%) were atopic. The IgE was 538.9 IU/mL and eosinophils was 649.8 cells/mm 3 . According to the on-label use of anti-IgE for asthma, only 20 patients would meet the criteria, 9 patients would be excluded due to IgE values, 16 due to non-severe asthma and 16 non-atopic patients. In relation to Anti-IL5, 35 patients would meet the criteria, and 17 patients were excluded because they presented non-severe asthma and 9 had eosinophils <300 cells/mm 3 . CONCLUSIONS: AERD is characterized by an eosinophilic inflammatory profile. This study showed that, according to the current criteria for monoclonal therapies, more patients would meet the criteria for anti-IL-5 due to the high frequency of peripheral eosinophilia and, on the other hand, the large number of non-atopic patients could restrict the use of anti-IgE.
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Lengthening omalizumab dosing interval in treatment of moderate to severe persistent asthma Varaz Bozoghlanian, MD, Saraleen Benouni, MD, Lee E. Sheinkopf, MD FAAAAI, Lananh T. Do, MD FAAAAI, and Roger M. Katz, MD FAAAAI; Allergy Asthma Care Center, Los Angeles, CA. RATIONALE: When chronic asthmatics are well controlled on omalizumab, can the dosing interval be lengthened? METHODS: A retrospective chart review was performed on 167 patients enrolled in studies utilizing omalizumab for treatment of moderate to severe persistent allergic asthma. Patients were included in our review if they continued omalizumab treatment for up to 48 months after initial omalizumab dosing of 300mg every 2-4 weeks for up to 6 months. RESULTS: At 12 months, 13 patients were able to lengthen their omalizumab interval by 2 weeks without exacerbation. At 18 months, 8 additional patients were able to lengthen their dosing, up to 10-12 week intervals. At 24 months, 65 patients remained in our cohort, and 8 had omalizumab dosing every 8-12 weeks. By 36 months, 46 patients remained in our cohort, and 10 had dosing every 8-12 weeks. By 48 months, 34 patients remained in our cohort (22 females and 12 males), and 31 were able to extend out to at least every 6 weeks or longer. Omalizumab dosing interval was not extended if patients were symptomatic, had exacerbations despite omalizumab, or due to patient preference. Reasons for dropout from our cohort included discontinuation of Xolair after asthma was controlled, changing to other treatments (including other biologics), and loss to follow-up. CONCLUSIONS: Our results suggest that a portion of asthma patients may eventually lengthen out their omalizumab dosing schedule without exacerbation. Larger studies are needed to ascertain which particular phenotypes may be more successful at lengthening the interval.
